GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » icad Inc (NAS:ICAD) » Definitions » ROE %

icad (ICAD) ROE % : 25.51% (As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is icad ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. icad's annualized net income for the quarter that ended in Dec. 2023 was $8.22 Mil. icad's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $32.23 Mil. Therefore, icad's annualized ROE % for the quarter that ended in Dec. 2023 was 25.51%.

The historical rank and industry rank for icad's ROE % or its related term are showing as below:

ICAD' s ROE % Range Over the Past 10 Years
Min: -226.47   Med: -51.44   Max: -2.4
Current: -15.03

During the past 13 years, icad's highest ROE % was -2.40%. The lowest was -226.47%. And the median was -51.44%.

ICAD's ROE % is ranked worse than
62.79% of 809 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs ICAD: -15.03

icad ROE % Historical Data

The historical data trend for icad's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

icad ROE % Chart

icad Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -226.47 -98.94 -29.19 -33.54 -14.19

icad Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.12 -45.37 -22.62 -17.96 25.51

Competitive Comparison of icad's ROE %

For the Medical Devices subindustry, icad's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


icad's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, icad's ROE % distribution charts can be found below:

* The bar in red indicates where icad's ROE % falls into.



icad ROE % Calculation

icad's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-4.847/( (34.902+33.417)/ 2 )
=-4.847/34.1595
=-14.19 %

icad's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=8.22/( (31.035+33.417)/ 2 )
=8.22/32.226
=25.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


icad  (NAS:ICAD) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=8.22/32.226
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(8.22 / 18.96)*(18.96 / 43.623)*(43.623 / 32.226)
=Net Margin %*Asset Turnover*Equity Multiplier
=43.35 %*0.4346*1.3537
=ROA %*Equity Multiplier
=18.84 %*1.3537
=25.51 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=8.22/32.226
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (8.22 / -2.144) * (-2.144 / -2.868) * (-2.868 / 18.96) * (18.96 / 43.623) * (43.623 / 32.226)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= -3.834 * 0.7476 * -15.13 % * 0.4346 * 1.3537
=25.51 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


icad ROE % Related Terms

Thank you for viewing the detailed overview of icad's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


icad (ICAD) Business Description

Traded in Other Exchanges
N/A
Address
98 Spit Brook Road, Suite 100, Nashua, NH, USA, 03062
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.
Executives
Eric Lonnqvist officer: See Remarks 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 02062
Daniel Joseph Shea officer: See Remarks 2 MINUTEMAN ROAD, MEDFIELD MA 02052
Jonathan Go officer: Sr. VP of R&D C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Stephen P Sarno officer: See Remarks C/O SAPIENT CORPORATION, 25 FIRST STREET, CAMBRIDGE MA 02141
Andy Sassine director 82 DEVONSHIRE STREET, BOSTON MA 02109
Dana R Brown director 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Timothy Norris Irish director 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Nathaniel Dalton director C/O AFFILIATED MANAGERS GROUP INC, 777 S. FLAGLER DR., SUITE 1201 E. TOWER, WEST PALM BEACH FL 33401
Susan Alyson Wood director 845 MORENO AVENUE, PALO ALTO CA 94303
Michael S Klein director C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
Charles Ross Carter officer: See Remarks C/O GI DYNAMICS, INC., 745 ATLANTIC AVENUE, BOSTON MA 02111
Stacey M Stevens officer: Executive VP of Marketing C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
R. Scott Areglado officer: Interim Chief FinancialOfficer 98 SPIT BROOK ROAD, SUITE 100, C/O ICAD, INC., NASHUA NH 03062
Rakesh Patel director 15400 NATIONAL AVENUE, LOS GATOS CA 95032
Dr Lawrence Howard director C/O PRESSTEK INC, 2 GREENWICH OFFICE PARK, GREENWICH CT 06831